臨床健康科学・臨床腫瘍学

医学講座HP http://www.f.kpu-m.ac.jp/c/kouza/igaku/ 

大学院科目名 臨床健康科学・臨床腫瘍学
スタッフ
教授  山中 龍也
 
 
助教      金山 知彦
研究員兼秘書  早野 あづさ
研修員     藤井 照久
研修員     田村 沙織
研究内容 治療困難な悪性脳腫瘍のゲノム解析から予後予測因子・バイオマーカー・標的分子を明らかにし、新しい診断法・治療法の開発を目標としています。また、臨床健康科学・臨床腫瘍学・臨床遺伝学領域の諸問題も研究対象範囲とします。
研究業績
  1. Koyama-Nasu R, Hayashi T, Nasu-Nishimura Y, Akiyama T and Yamanaka R : Thr160 of Axin1 is critical for the formation and function of the -catenin destruction complex. Biochemical Biophysical Res Comm 459(3):411-415, 2015
  2. Kawaguchi A, Yajima N, Tsuchiya N, Homma J, Sano M, Natsumeda M, Takahashi H, Fujii Y, Kakuma T, Yamanaka R: Gene expression signature-based prognostic risk score in patients with glioblastoma. Cancer Sci 104(9):1205-1210, 2013.
  3. Kawaguchi A, Iwadate Y, Komohara Y, Sano M, Kajiwara K, Yajima N, Tsuchiya N, Homma J, Aoki H, Kobayashi T, Sakai Y, Hondoh H, Fujii Y, Kakuma T, Yamanaka R: Gene expression signature–based prognostic risk score in patients with primary central nervous system lymphoma. Clin Cancer Res 18(20):5672-5781, 2012.
  4. Kawaguchi A, Yajima N, Komohara Y, Aoki H, Tsuchiya N, Homma J, Sano M, Natsumeda M, Uzuka T, Saitoh A, Takahashi H, Sakai Y, Takahashi H, Fujii Y, Kakuma T, Yamanaka R: Identification and validation of a gene expression signature that predicts outcome in malignant glioma patients. Int J Oncol 40(3):721-730, 2012.
  5. Yamanaka R, Saya H: Molecularly targeted therapies for glioma. Ann Neurol 66:717-729, 2009.
  6. Li J, Okamoto H, Yin C, Takizawa J, Aoki S, Gläsker S, Rushing EJ, Vortmeyer AO, Oldfield EH, Yamanaka R, Zhuang Z: Proteomic characterization of primary CNS diffuse large B-cell lymphomas. J Neurosurg 109(3):536-546, 2008.
  7. Fukai J, Yokote H, Yamanaka R, Arao T, Nishio K, Itakura T : EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line. Mol Cancer Ther 7(9):2768-2678, 2008.
  8. Yamanaka R, Shinbo Y, Sano M, Homma J, Tsuchiya N, Yajima N, Tamura T, Hondoh H, Takahashi H, Morii K, Onda K, Tanaka R: Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen. Leuk Lymphoma 48(6):1119-1126, 2007.
  9. Yamanaka R, Arao T, Yajima N, Tsuchiya N, Homma J, Tanaka R, Sano M, Oide A, Sekijima M, Nishio K :Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 25(44): 5994-6002, 2006.
  10. Tsuchiya N, Yamanaka R, Yajima N, Homma J, Sano M, Komata T, Ikeda T, Fujimoto I, Takahashi H, Tanaka R, Ikenaka K: Isolation and characterization of an N-Linked oligosaccharide that is increased in glioblastoma tissue and cell line. Int J Oncol 27(5):1231-1239, 2005.
  11. Yajima N, Yamanaka R, Mine T, Tsuchiya N, Homma J, Sano M, Kuramoto T, Obata Y, Komatsu N, Arima Y, Yamada A, Shigemori M, Itoh K, Tanaka R : Immunological evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 11(16):5900-5911, 2005.
  12. Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, Tanaka R: Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11(11):4160-4167, 2005.
問い合わせ先

TEL:075-212-5429

FAX:
e-mail:ryaman@koto.kpu-m.ac.jp

教室独自のHP

 http://www.f.kpu-m.ac.jp/c/kouza/igaku/

COPYRIGHT (C) 2012 KYOTO PREFECTURAL UNIVERSITY OF MEDICINE ALL RIGHTS RESERVED.